Daun Bahr

433 total citations
7 papers, 321 citations indexed

About

Daun Bahr is a scholar working on Neurology, Psychiatry and Mental health and Surgery. According to data from OpenAlex, Daun Bahr has authored 7 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Neurology, 2 papers in Psychiatry and Mental health and 1 paper in Surgery. Recurrent topics in Daun Bahr's work include Parkinson's Disease Mechanisms and Treatments (4 papers), Neurological disorders and treatments (2 papers) and Diagnosis and Treatment of Venous Diseases (1 paper). Daun Bahr is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (4 papers), Neurological disorders and treatments (2 papers) and Diagnosis and Treatment of Venous Diseases (1 paper). Daun Bahr collaborates with scholars based in United Kingdom, United States and Germany. Daun Bahr's co-authors include Roger Mills, Hilde Williams, Ann Johnson, Joseph H. Friedman, Herbert Y. Meltzer, Bernard Ravina, Tiffini Voss, Jeffrey L. Cummings, Joan Perelló and Smeeta Sinha and has published in prestigious journals such as Neuropsychopharmacology, Nephrology Dialysis Transplantation and Alzheimer s & Dementia.

In The Last Decade

Daun Bahr

7 papers receiving 312 citations

Peers

Daun Bahr

NEURO

CMN

PMH

CN

CP

Joshua Burke United States

Laura Ferri Italy

Randall Kaye United States

Federico Carbone Austria

Chizoba C. Umeh United States

María Verónica Rey France

Victor Abler United States

P. De Domenico Italy

Michele Ulrich Canada

J. David Grimes Canada

Joshua Burke United States

Daun Bahr

229 ×1.2

NEURO

79 ×0.7

CMN

285 ×3.7

PMH

39 ×0.9

CN

27 ×0.7

CP

Citations per year, relative to Daun Bahr Daun Bahr (= 1×) peers Joshua Burke

Countries citing papers authored by Daun Bahr

Since Specialization

Citations

This map shows the geographic impact of Daun Bahr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daun Bahr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daun Bahr more than expected).

Fields of papers citing papers by Daun Bahr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daun Bahr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daun Bahr. The network helps show where Daun Bahr may publish in the future.

Co-authorship network of co-authors of Daun Bahr

This figure shows the co-authorship network connecting the top 25 collaborators of Daun Bahr. A scholar is included among the top collaborators of Daun Bahr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daun Bahr. Daun Bahr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Brandenburg, Vincent, Smeeta Sinha, José‐Vicente Torregrosa, et al.. (2019). Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. Journal of Nephrology. 32(5). 811–821. 28 indexed citations

2.

Brandenburg, Vincent, Smeeta Sinha, José‐Vicente Torregrosa, et al.. (2018). FO020A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS. Nephrology Dialysis Transplantation. 33(suppl_1). i9–i9. 2 indexed citations

3.

Ballard, Clive, Roger Mills, Hilde Williams, et al.. (2013). O4–05–04: Antipsychotic efficacy and good tolerability in a Phase III placebo‐controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP‐103–020). Alzheimer s & Dementia. 9(4S_Part_17). 1 indexed citations

4.

Voss, Tiffini, Daun Bahr, Jeffrey L. Cummings, et al.. (2012). Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism & Related Disorders. 19(3). 295–299. 61 indexed citations

5.

Mills, Roger, Daun Bahr, & Hywel C Williams. (2011). 2.277 OPTIMIZATION OF PHASE III STUDY DESIGN FOR PIMAVANSERIN IN THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS (PDP). Parkinsonism & Related Disorders. 18. S134–S134. 4 indexed citations

6.

Meltzer, Herbert Y., Roger Mills, Hilde Williams, et al.. (2009). Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis. Neuropsychopharmacology. 35(4). 881–892. 224 indexed citations

7.

Fernandez, Hubert, et al.. (2009). P1.181 Parkinson's Disease Psychosis (PDP): An under-diagnosed condition in spite of its prevalence and impact. Parkinsonism & Related Disorders. 15. S75–S75. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact